Company news

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) news

Praxis Precision Medicines, Inc. news releases on 6ix. Latest, Oct 2, 2026: Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing…

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) news

Press releases & updates

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026

Praxis Precision Medicines and Remagine Labs Announce Strategic Collaboration to Develop Transdermal Ulixacaltamide for Essential Tremor

Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies

Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants

Praxis Precision Medicines to Participate in Goldmans Sachs 47th Annual Global Healthcare Conference

Praxis Precision Medicines Provides Vormatrigine Program Update

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results

Praxis Precision Medicines to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026, and Participate in Upcoming Investor Conference

Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor

Praxis to Showcase Essential3, the First Positive Phase 3 Program in Essential Tremor, at AAN 2026

Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy

Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs

Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results

Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences

SEQSTER Announces Expanded Partnership with Praxis Precision Medicines to Accelerate Clinical Trials in CNS Disorders

Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy

Praxis Precision Medicines Enters Its Next Chapter Following a Pivotal Year of Progress

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments

Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering

Praxis Precision Medicines, Inc. Announces Proposed Public Offering

Praxis Precision Medicines Announces the FDA Has Granted Breakthrough Therapy Designation for Ulixacaltamide HCl in Essential Tremor

Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026

Praxis Precision Medicines Announces Alignment with FDA on Simplified and Accelerated Registrational Pathway for Elsunersen in Early Onset SCN2A Developmental and Epileptic Encephalopathy

Praxis AES Wrap-up: Best-in-Class Potential Across Rare Pediatric and Adult Epilepsies

Praxis Precision Medicines Announces Positive Results from EMBOLD Study for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies

Praxis Precision Medicines Announces Positive Pre-NDA Meeting with FDA for Ulixacaltamide in Essential Tremor

Praxis to present latest preclinical and clinical advancements across leading epilepsy portfolio at the 2025 American Epilepsy Society (AES) Annual Meeting

Praxis Precision Medicines to Participate in Upcoming Fireside Chat

Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Praxis Precision Medicines to Participate in Upcoming Investor Conferences

Praxis announces accelerated development path for relutrigine in SCN2A and SCN8A DEE patients following positive FDA feedback

Praxis Precision Medicines, Inc. Announces Pricing of $525 Million Public Offering

Praxis Precision Medicines Announces Positive Topline Results from Two Pivotal Phase 3 Studies of Ulixacaltamide HCl in the Essential3 Program for Essential Tremor

Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets

ReCode Therapeutics Announces Over $29 Million in Additional Financing to Advance Genetic Medicines Pipeline and Provides Corporate Update

Praxis Precision Medicines to Participate in September Investor Conferences

Praxis Medicines to Present at 36th International Epilepsy Congress 2025 in Lisbon, Showcasing Latest RADIANT Study Data and Leading Precision Epilepsy Pipeline

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Praxis Precision Medicines Announces Positive, Best-in-Disease Topline Results in Patients with Focal Onset Seizures from the RADIANT Study of Vormatrigine

Praxis Precision Medicines to Host Conference Call to Announce Topline Results from the RADIANT Trial and Provide Second Quarter 2025 Financial Results

Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Relutrigine for the Treatment of Seizures Associated with SCN2A and SCN8A Developmental and Epileptic Encephalopathies

Praxis Precision Medicines to Participate in Upcoming Conferences

Praxis Precision Medicines Highlights DEE Clinical Program Updates at Virtual Investor Event

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results

Praxis Precision Medicines to Hold Virtual Investor Event to Discuss Clinical Programs in Developmental and Epileptic Encephalopathies

Praxis Precision Medicines to Participate in Upcoming April Conferences

Praxis Precision Medicines to Present on Late-Stage Programs across Epilepsy and Movement Disorders at the American Academy of Neurology 2025 Annual Meeting